View ValuationInventiva 향후 성장Future 기준 점검 3/6Inventiva (는) 각각 연간 53% 및 51.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 40.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 33.8% 로 예상됩니다.핵심 정보53.0%이익 성장률40.08%EPS 성장률Biotechs 이익 성장22.7%매출 성장률51.3%향후 자기자본이익률33.81%애널리스트 커버리지Good마지막 업데이트12 Jun 2026최근 향후 성장 업데이트Breakeven Date Change • Oct 29No longer forecast to breakevenThe 7 analysts covering Inventiva no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.7m in 2027. New consensus forecast suggests the company will make a loss of €23.8m in 2027.Breakeven Date Change • Oct 01Forecast to breakeven in 2027The 8 analysts covering Inventiva expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% per year to 2026. The company is expected to make a profit of €15.7m in 2027. Average annual earnings growth of 52% is required to achieve expected profit on schedule.모든 업데이트 보기Recent updates공시 • Jun 04Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 27,272,727 Price\Range: $4.4 Discount Per Security: $0.264공시 • Jun 03Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners LimitedInventiva S.A. entered into an agreement with funds and accounts managed by new investors BlackRock, Inc., and Claret Capital Partners Limited on June 1, 2026. The company will issue a first tranche for a maximum amount of €35 million consisting of senior secured convertible bonds, convertible into new ordinary shares, subject to satisfaction of certain closing conditions; a second tranche for a maximum amount of €40 million consisting of senior secured amortized bonds, subject to satisfaction of certain closing conditions; and a third tranche for a maximum amount of €55 million consisting of senior secured amortized bonds, available for the company to draw at its election until February 15, 2027. The company also has an optional additional tranche for a maximum amount of €20 million, subject to mutual consent, following the approval of the NDA for NATiV3. Pursuant to the terms of the subscription agreement, the lenders will receive warrants exercisable for up to €6.75 million worth of ordinary shares (or up to €12.35 million in the event of a shortfall event, as described below), expected to be granted concurrently with the drawdown of tranches A and B €2.75 million worth of ordinary shares are expected to be granted concurrently with the drawdown of tranche C.공시 • May 26Inventiva S.A., Annual General Meeting, Jun 30, 2026Inventiva S.A., Annual General Meeting, Jun 30, 2026. Location: hotel villa m 24 30 boulevard pasteur, paris France공시 • Apr 25Inventiva Announces Executives ChangesInventiva announced new members of its leadership team: Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These recruitments strengthen Inventiva’s leadership team as the Company prepares for the top-line data readout from the NATiV3 Phase 3 trial evaluating lanifibranor, expected in the fourth quarter of 2026. The new team members bring robust financial management, strong legal and governance oversight, and organizational expertise in building high-performing teams, positioning Inventiva to navigate its next phase of growth with confidence and discipline. Jean Volatier and Nathalie Harroy, who have respectively served as Chief Financial Officer and Head of Human Resources and have been with Inventiva since its inception, have played a key role in the Company’s development over the years and bring deep institutional knowledge. Jean Volatier will transition to the role of EVP Finance & Corporate Social Responsibility, where he will continue to support the Company on key strategic priorities. Nathalie Harroy will also remain with Inventiva, continuing to contribute her experience and expertise to the organization. The Company is pleased that both will remain part of Inventiva and continue to support its next phase of growth. Coles comes to Inventiva from Vivet Therapeutics, where she was head of Legal and Finance involved in all strategic and operational aspects of the business from the creation of the company through negotiations of an option to purchase deal with Pfizer. She previously was general counsel at Inventiva from 2012-2014 and again from 2019-2021, during its Nasdaq listing. Coles has also served as Supervisory Board member of TME Pharma. Her experience across both public and private life science companies includes managing legal, compliance, intellectual property, corporate governance, board, and investor relations including activities around cross-border contracting, licensing, mergers and acquisitions, and business development. Herbster comes to Inventiva from Sage Therapeutics, where she led both human resources and business operations. During her six years at Sage, she drove people-centric strategies and initiatives that fostered the company’s culture and commercial growth and supported the eventual acquisition of Sage by Supernus Pharmaceuticals. Prior to Sage, Herbster held a global role at EMD Serono/Merck KGaA, managing Regulatory Affairs, Business Development & Alliance Management, as well as serving as the US Site Head for Research and Development. Prior to EMD Serono, she spent several years at Biogen serving in business partner roles of increasing scope and responsibility and her formative years within Human Resources at Johnson & Johnson. Her experience spans various facets of the industry, including mergers and acquisitions, divestitures, and the successful launch of consumer products, medical devices, and pharmaceuticals.Reported Earnings • Apr 01Full year 2025 earnings released: €1.90 loss per share (vs €3.08 loss in FY 2024)Full year 2025 results: €1.90 loss per share. Net loss: €354.1m (loss widened 92% from FY 2024). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.공시 • Jan 15+ 1 more updateInventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026Inventiva S.A. announced that they will report fiscal year 2025 results on Mar 30, 2026공시 • Nov 14Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 38,961,038 Price\Range: $3.85 Discount Per Security: $0.231공시 • Nov 13Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock)Breakeven Date Change • Oct 29No longer forecast to breakevenThe 7 analysts covering Inventiva no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.7m in 2027. New consensus forecast suggests the company will make a loss of €23.8m in 2027.공시 • Oct 16Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market OfferingReported Earnings • Oct 03First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.공시 • Oct 02+ 1 more updateInventiva Announces CEO ChangesInventiva announced the appointment of Andrew Obenshain as Chief Executive Officer of the Company. He succeeds Frédéric Cren, the Company’s co-founder, who has served as CEO since its inception in 2012. Mr. Cren is also stepping down from the Board of Directors and will work with Mr. Obenshain to ensure a smooth transition and continuity in the Company’s strategic priorities. Mr. Obenshain was previously the CEO of bluebird bio, recently renamed Genetix Biotherapeutics, where he led the company’s transformation into a global commercial-stage gene therapy enterprise, successfully securing multiple regulatory approvals across major geographies. He brings more than 20 years of global leadership in drug development, regulatory strategy, and commercialization across the United States, Europe, and international markets. Prior to bluebird, Mr. Obenshain held senior leadership roles at Shire and Genzyme/Sanofi in France, with a focus on rare diseases and specialty therapeutics. He holds a B.A. in Genetics, Cell & Developmental Biology from Dartmouth College and an M.B.A. from Northwestern University’s Kellogg School of Management.Reported Earnings • Oct 01First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe.Breakeven Date Change • Oct 01Forecast to breakeven in 2027The 8 analysts covering Inventiva expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% per year to 2026. The company is expected to make a profit of €15.7m in 2027. Average annual earnings growth of 52% is required to achieve expected profit on schedule.이익 및 매출 성장 예측XTRA:6IV - 애널리스트 향후 추정치 및 과거 재무 데이터 (EUR Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028213-5980341012/31/2027118-913412001112/31/20265-148-47-741112/31/20257-354-105-105N/A9/30/202512-333-98-98N/A6/30/202517-311-91-91N/A3/31/202516-248-89-89N/A12/31/202414-184-86-86N/A9/30/202417-144-86-85N/A6/30/202419-104-85-85N/A3/31/202421-107-84-83N/A12/31/202323-110-82-82N/A9/30/202322-95-73-73N/A6/30/202322-80-64-64N/A3/31/202320-67-55-54N/A12/31/202218-54-45-45N/A9/30/202214-55-50-49N/A6/30/202210-56-55-54N/A3/31/202210-56-54-53N/A12/31/20219-50-48-48N/A9/30/20217-45-46-45N/A6/30/20216-41-44-43N/A3/31/20215-36-35-35N/A12/31/20205-34-31-31N/A9/30/20207-29-24-24N/A6/30/202010-25-17-17N/A3/31/202010-27-23-23N/A12/31/201911-30-29-28N/A9/30/20199-34N/A-33N/A6/30/20197-37N/A-38N/A3/31/20198-35N/A-35N/A12/31/20187-33N/A-34N/A9/30/20188-29N/A-27N/A6/30/20189-25N/A-21N/A3/31/20189-22N/A-19N/A12/31/201710-19N/A-17N/A9/30/201711-16N/A-18N/A6/30/201713-13N/A-19N/A3/31/201714-10N/A-17N/A12/31/201614-7N/A-15N/A9/30/201613-8N/A-14N/A6/30/201612-8N/A-13N/A3/31/201610-9N/A-13N/A12/31/20159-9N/A-14N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 6IV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 6IV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 6IV 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 6IV 의 수익(연간 51.3%)이 German 시장(연간 6.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 6IV 의 수익(연간 51.3%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 6IV의 자본 수익률은 3년 후 33.8%로 높을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/16 18:43종가2026/06/16 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Inventiva S.A.는 22명의 분석가가 다루고 있습니다. 이 중 11명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Eliana MerleBarclaysEdward NashCanaccord GenuityEtzer DaroutGuggenheim Securities, LLC19명의 분석가 더 보기
Breakeven Date Change • Oct 29No longer forecast to breakevenThe 7 analysts covering Inventiva no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.7m in 2027. New consensus forecast suggests the company will make a loss of €23.8m in 2027.
Breakeven Date Change • Oct 01Forecast to breakeven in 2027The 8 analysts covering Inventiva expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% per year to 2026. The company is expected to make a profit of €15.7m in 2027. Average annual earnings growth of 52% is required to achieve expected profit on schedule.
공시 • Jun 04Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $119.999999 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 27,272,727 Price\Range: $4.4 Discount Per Security: $0.264
공시 • Jun 03Inventiva S.A. announced that it expects to receive €130 million in funding from BlackRock, Inc., Claret Capital Partners LimitedInventiva S.A. entered into an agreement with funds and accounts managed by new investors BlackRock, Inc., and Claret Capital Partners Limited on June 1, 2026. The company will issue a first tranche for a maximum amount of €35 million consisting of senior secured convertible bonds, convertible into new ordinary shares, subject to satisfaction of certain closing conditions; a second tranche for a maximum amount of €40 million consisting of senior secured amortized bonds, subject to satisfaction of certain closing conditions; and a third tranche for a maximum amount of €55 million consisting of senior secured amortized bonds, available for the company to draw at its election until February 15, 2027. The company also has an optional additional tranche for a maximum amount of €20 million, subject to mutual consent, following the approval of the NDA for NATiV3. Pursuant to the terms of the subscription agreement, the lenders will receive warrants exercisable for up to €6.75 million worth of ordinary shares (or up to €12.35 million in the event of a shortfall event, as described below), expected to be granted concurrently with the drawdown of tranches A and B €2.75 million worth of ordinary shares are expected to be granted concurrently with the drawdown of tranche C.
공시 • May 26Inventiva S.A., Annual General Meeting, Jun 30, 2026Inventiva S.A., Annual General Meeting, Jun 30, 2026. Location: hotel villa m 24 30 boulevard pasteur, paris France
공시 • Apr 25Inventiva Announces Executives ChangesInventiva announced new members of its leadership team: Susan Coles as Chief Legal Officer, and Pamela Herbster as Chief People Officer. These recruitments strengthen Inventiva’s leadership team as the Company prepares for the top-line data readout from the NATiV3 Phase 3 trial evaluating lanifibranor, expected in the fourth quarter of 2026. The new team members bring robust financial management, strong legal and governance oversight, and organizational expertise in building high-performing teams, positioning Inventiva to navigate its next phase of growth with confidence and discipline. Jean Volatier and Nathalie Harroy, who have respectively served as Chief Financial Officer and Head of Human Resources and have been with Inventiva since its inception, have played a key role in the Company’s development over the years and bring deep institutional knowledge. Jean Volatier will transition to the role of EVP Finance & Corporate Social Responsibility, where he will continue to support the Company on key strategic priorities. Nathalie Harroy will also remain with Inventiva, continuing to contribute her experience and expertise to the organization. The Company is pleased that both will remain part of Inventiva and continue to support its next phase of growth. Coles comes to Inventiva from Vivet Therapeutics, where she was head of Legal and Finance involved in all strategic and operational aspects of the business from the creation of the company through negotiations of an option to purchase deal with Pfizer. She previously was general counsel at Inventiva from 2012-2014 and again from 2019-2021, during its Nasdaq listing. Coles has also served as Supervisory Board member of TME Pharma. Her experience across both public and private life science companies includes managing legal, compliance, intellectual property, corporate governance, board, and investor relations including activities around cross-border contracting, licensing, mergers and acquisitions, and business development. Herbster comes to Inventiva from Sage Therapeutics, where she led both human resources and business operations. During her six years at Sage, she drove people-centric strategies and initiatives that fostered the company’s culture and commercial growth and supported the eventual acquisition of Sage by Supernus Pharmaceuticals. Prior to Sage, Herbster held a global role at EMD Serono/Merck KGaA, managing Regulatory Affairs, Business Development & Alliance Management, as well as serving as the US Site Head for Research and Development. Prior to EMD Serono, she spent several years at Biogen serving in business partner roles of increasing scope and responsibility and her formative years within Human Resources at Johnson & Johnson. Her experience spans various facets of the industry, including mergers and acquisitions, divestitures, and the successful launch of consumer products, medical devices, and pharmaceuticals.
Reported Earnings • Apr 01Full year 2025 earnings released: €1.90 loss per share (vs €3.08 loss in FY 2024)Full year 2025 results: €1.90 loss per share. Net loss: €354.1m (loss widened 92% from FY 2024). Revenue is forecast to grow 53% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
공시 • Jan 15+ 1 more updateInventiva S.A. to Report Fiscal Year 2025 Results on Mar 30, 2026Inventiva S.A. announced that they will report fiscal year 2025 results on Mar 30, 2026
공시 • Nov 14Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million.Inventiva S.A. has completed a Follow-on Equity Offering in the amount of $149.999996 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Securities Offered: 38,961,038 Price\Range: $3.85 Discount Per Security: $0.231
공시 • Nov 13Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $125 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock)
Breakeven Date Change • Oct 29No longer forecast to breakevenThe 7 analysts covering Inventiva no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of €15.7m in 2027. New consensus forecast suggests the company will make a loss of €23.8m in 2027.
공시 • Oct 16Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million.Inventiva S.A. has filed a Follow-on Equity Offering in the amount of $100 million. Security Name: Ordinary Shares Security Type: Common Stock Transaction Features: At the Market Offering
Reported Earnings • Oct 03First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in Europe.
공시 • Oct 02+ 1 more updateInventiva Announces CEO ChangesInventiva announced the appointment of Andrew Obenshain as Chief Executive Officer of the Company. He succeeds Frédéric Cren, the Company’s co-founder, who has served as CEO since its inception in 2012. Mr. Cren is also stepping down from the Board of Directors and will work with Mr. Obenshain to ensure a smooth transition and continuity in the Company’s strategic priorities. Mr. Obenshain was previously the CEO of bluebird bio, recently renamed Genetix Biotherapeutics, where he led the company’s transformation into a global commercial-stage gene therapy enterprise, successfully securing multiple regulatory approvals across major geographies. He brings more than 20 years of global leadership in drug development, regulatory strategy, and commercialization across the United States, Europe, and international markets. Prior to bluebird, Mr. Obenshain held senior leadership roles at Shire and Genzyme/Sanofi in France, with a focus on rare diseases and specialty therapeutics. He holds a B.A. in Genetics, Cell & Developmental Biology from Dartmouth College and an M.B.A. from Northwestern University’s Kellogg School of Management.
Reported Earnings • Oct 01First half 2025 earnings released: €1.62 loss per share (vs €0.94 loss in 1H 2024)First half 2025 results: €1.62 loss per share (further deteriorated from €0.94 loss in 1H 2024). Revenue: €5.61m (up 105% from 1H 2024). Net loss: €175.9m (loss widened 259% from 1H 2024). Revenue is forecast to grow 56% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Biotechs industry in Europe.
Breakeven Date Change • Oct 01Forecast to breakeven in 2027The 8 analysts covering Inventiva expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% per year to 2026. The company is expected to make a profit of €15.7m in 2027. Average annual earnings growth of 52% is required to achieve expected profit on schedule.